在认知障碍中使用马隆迪化物:系统性审查和元分析
Stefano Zoroddu1, Stefania Sedda1, Arduino A Mangoni2
1Department of Biomedical Sciences, University of Sassari, Sassari 07100, Italy.
Neuroscience and biobehavioral reviews
|December 22, 2025
概括
在患有阿尔茨海默氏症或轻度认知障碍的人群中,循环中的恶性二甲酸 (MDA) 是氧化应激的标志物,显著增加. 这一发现支持MDA作为神经退行症早期生物标志物的潜力.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
背景情况:
- 马隆迪甲基 (MDA) 表示脂质过氧化和氧化应激.
- 这些过程与神经退行和认知衰退有关.
研究的目的:
- 在阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 中系统地审查和元分析循环MDA度.
- 将认知障碍患者的MDA水平与健康对照进行比较.
主要方法:
- 在PubMed,Scopus和Web of Science的系统文献搜索.
- 36项研究的元分析 (2132名患者,2169名对照).
- 根据样本类型,地区和分析方法进行子组分析;用于出版偏差的剪切和填充分析.
主要成果:
- 在认知障碍个体中,MDA度显著更高 (SMD = 1.46).
- 在AD (SMD = 0.82) 和MCI (SMD = 1.24) 组中观察到MDA升高.
- 尽管分析方法各不相同,但在所有样本类型和地区的调查结果都是稳定的.
结论:
- 循环MDA在认知障碍中升高,表明其作为生物标志物的作用.
- MDA可能是早期神经退行和氧化应激的指标.
- 建议对测量进行标准化,并进一步研究预后效用.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
503
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
Dementia
482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
482
Long-term Depression
3.0K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.0K


